Fig. 2From: Liquid chromatography-tandem mass spectrometry for pharmacokinetics evaluation of AZD5305, a selective PARP1 inhibitor, in miceLC–MS/MS chromatograms of AZD5305 (left) and olaparib (right): a after deproteinization of blank mice plasma, b zero sample, c LLOQ, and d 1 h after PO administration of AZD5305 at a dose of 1 mg/kg in miceBack to article page